Trending...
- FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
- Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
- Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
SANDUSKY, Ohio, July 31, 2020 /PRNewswire/ -- PAO Group, Inc. (USOTC: PAOG) today previewed its next acquisition after just this week closing the acquisition of a cannabis biopharmaceutical asset to treat Chronic Obstructive Pulmonary Disease (COPD) and a cannabis cultivation operation developing a proprietary cannabis cultivar.
The COPD treatment, RespRx, is derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."
PAOG anticipates soon entering into a Contract Research Organization (CRO) agreement in conjunction with advancing an Investigational New Drug Application (IND) to ultimately achieve Food and Drug Administration (FDA) approval for RespRx as a COPD treatment.
Based on positive results from an informal trial of RexpRX with 25 COVID-19 patients, PAOG also plans to make Coronavirus Treatment Acceleration Program (CTAP) application after entering into a CRO agreement.
More on Ohio Pen
PAOG has a working agreement to close the acquisition of the underlying extraction patent in conjunction with executing the CRO agreement. The CRO agreement and corresponding acquisition are anticipated to close by the end of August.
CEO James C. DiPrima discusses the PAOG CRO, IND and CTAP developments in his interview on MoneyTV with Donald Baillargeon released today.
MoneyTV with Donald Baillargeon is the internationally syndicated television program all about money and what makes it happen, featuring informative interviews with company CEOs and executives, providing insights into their operations and outlooks for their futures. MoneyTV is seen in over 200 million TV households in more than 75 countries.
The MoneyTV Interview is available at www.moneytv.net and will be syndicated across multiple channels and platforms.
More on Ohio Pen
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
CONTACT INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
[email protected]
SOURCE PAO Group, Inc.
The COPD treatment, RespRx, is derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."
PAOG anticipates soon entering into a Contract Research Organization (CRO) agreement in conjunction with advancing an Investigational New Drug Application (IND) to ultimately achieve Food and Drug Administration (FDA) approval for RespRx as a COPD treatment.
Based on positive results from an informal trial of RexpRX with 25 COVID-19 patients, PAOG also plans to make Coronavirus Treatment Acceleration Program (CTAP) application after entering into a CRO agreement.
More on Ohio Pen
- New Website Highlights AI Specialist Joshua Terrell's Work in and Around Dublin, Ohio
- Infinity Infusion Solutions Named Finalist for D Magazine's D CEO 2026 Excellence in Healthcare Awards
- Canadian Tint Expo 2027: Why Every Window Tinter Should Compete in Niagara Falls on April 3rd & 4th
- Building a Diversified Healthcare Platform as Exosome Science, Telehealth, Diagnostics & Strategic Acquisitions Converge: NexTel Medical (OTCID: MAJI)
- Most Indiana Plane Crashes Happen Away from the State's Major Airports
PAOG has a working agreement to close the acquisition of the underlying extraction patent in conjunction with executing the CRO agreement. The CRO agreement and corresponding acquisition are anticipated to close by the end of August.
CEO James C. DiPrima discusses the PAOG CRO, IND and CTAP developments in his interview on MoneyTV with Donald Baillargeon released today.
MoneyTV with Donald Baillargeon is the internationally syndicated television program all about money and what makes it happen, featuring informative interviews with company CEOs and executives, providing insights into their operations and outlooks for their futures. MoneyTV is seen in over 200 million TV households in more than 75 countries.
The MoneyTV Interview is available at www.moneytv.net and will be syndicated across multiple channels and platforms.
More on Ohio Pen
- L2 Aviation Welcomes Jason Marshall as Vice President of Sales and Business Development
- New Vintage Toys Store, The Toy Shack, Buys, Sells & Trades Star Wars, Legos Servicing Cincinnati OH
- Mom Era, Still That Girl: Family Art Tees 25% Off
- Best New Marketing Concepts of 2026
- Fashion vs. Fascism - Because Democracy Should Always Be In Style
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
CONTACT INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
[email protected]
SOURCE PAO Group, Inc.
0 Comments
Latest on Ohio Pen
- Super Rooter Expands to 190 Plumbing, Sewer, and Drain Service Locations Across the United States
- European Patent for ALS Program Expands the Story: HOPE Deploys Robotic TMS & FDA Commercialization Path Advances: NRx Pharmaceuticals: NAS DAQ: NRXP
- VICTURY Sports Announces Formation of Youth Sports League Built on the Official, Patented, and Award-Winning Keepy Uppy® Ball
- The Importance of Sharing Artistic Experiences: Joshua C. Terrell's Creative Work Around Ohio
- Highlighting the Importance of Accessible, Experience-Based Finance Writing by Joshua Terrell
- Congressman Chuck Edwards (NC-11) Presents ReadyCommunities Partnership 2026 National Service Award to Local Businessman / US Air Force Veteran
- Cress Creeks Farm Opens Fall Corn Maze and Baby Lamb Hayride Experience in Ellijay, Georgia
- Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
- Ohio State Parks Foundation Names Christopher Gillcrist Executive Director
- Cleveland's Puerto Rican Community Takes Center Stage: Inaugural Boricua Block Party Set for Sep 12
- Kerri Lawless Introduces New Home-Selling Option for Local Homeowners
- FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
- Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
- Shelter Structures America makes European debut at TEMPOR EXPO 2026 in Fulda, Germany
- HydroExcavation.com Relaunches With Exclusive Local Service Areas and Dedicated Hydrovac Manufacturer Directory
- Sky Quarry Enters a Powerful New Chapter: Refinery Restart Emminent, Nevada Oil Initiative and Visibility Put (NAS DAQ: SKYQ) in the Spotlight
- OneVizion Launches Vera AI, Bringing Connected Operational Context to Infrastructure Teams
- P-Wave Press Announces Pushing the Wave 2025 by L.A. Davenport
- DONGSHENG Titanium Recycling: Promoting a Closed-Loop Cycle for High-End Titanium Materials
- French Camp Academy Releases New Video Inviting Individuals to Consider a Life of Service